<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604471</url>
  </required_header>
  <id_info>
    <org_study_id>2016/26OCT/471</org_study_id>
    <nct_id>NCT03604471</nct_id>
  </id_info>
  <brief_title>Lipid-lowering Therapy Individualization</brief_title>
  <official_title>Lipid-lowering Therapy Individualization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will explore individual factors influencing statin pharmacokinetics in a
      cohort of 150 patients treated with atorvastatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atorvastatin is widely prescribed for the treatment of hypercholesterolemia to prevent the
      risk of cardiovascular diseases, a leading death cause in industrialized countries. There
      exists considerable inter-individual variability in response to statins, reflected by
      differences in lipid-lowering effect or risk of presenting adverse drug reaction; mainly
      myotoxicity. A plethora of different factors (demographic, genetic, physiopathologic,
      environmental...) have been tested to explain this variability but it lacks of
      pharmacokinetic (PK) data and/or replications of observations are rare and results remain
      inconclusive, probably because of non-adapted designs and no-clear driven-hypothesis but also
      due to a lack of scientific rationale and deep mechanistic understanding. This clinical study
      will explore individual factors influencing statin PK in a cohort of 150 patients treated
      with atorvastatin. The collection of meticulous clinical PK data and a rigorous statistical
      analysis will allow quantifying the effect of each identified parameter on statin PK and
      eventually, defining a population-based PK model taking into account the combined effect of
      all covariates in a quantitative approach. This innovative prospectively designed clinical
      study will ultimately allow predicting atorvastatin PK fluctuations and anticipating any
      inadequate dosing in clinical care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2017</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">August 27, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atorvastatin population pharmacokinetics</measure>
    <time_frame>18 months</time_frame>
    <description>Concentrations of atorvastatin acid (pmol/ml) will be measured by HPLC-MS using sparse samples obtained over the entire study period. Data will be pooled and analyzed using population pharmacokinetic modeling. The reported pharmacokinetic parameters will depend on the type of model that best fits the data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atorvastatin metabolites population pharmacokinetics</measure>
    <time_frame>18 months</time_frame>
    <description>Concentrations of ortho-hydroxyatorvastatin (pmol/ml), para-hydroxyatorvastatin (pmol/ml) and atorvastatin lactone (pmol/ml) will be measured by HPLC-MS using sparse samples obtained over the entire study period. Data will be pooled and analyzed using population pharmacokinetic modeling. The reported pharmacokinetic parameters will depend on the type of model that best fits the data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of total cholesterol, LDL cholesterol and HDL cholesterol at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine kinase</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of creatine kinase at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse drug events</measure>
    <time_frame>18 months</time_frame>
    <description>Reports of adverse drug events will be recorded at each visit using a standardized questionnaire that includes the following categories : muscle cramps (grade 1 to 5), muscle pain (graded 1 to 5), rhabdomyolysis, gastro-intestinal side effects (Nauseas, diarrhea or vomitus), other side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogene genotype</measure>
    <time_frame>18 months</time_frame>
    <description>Patients will be genotyped for single nucleotide polymorphisms of interest in the following genes : ABCB1, ABCC1, ABCC2, ABCC4, ABCC5, ABCG2, CYP3A4, CYP3A5, NR1I2, POR, PPARalpha, SLCO1B1, SLCO2B1, SLCO3A1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of triglyceride levels at each visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Blood sampling for atorvastatin quantification and pharmacogenetic analysis.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with atorvastatin (any dose)

        Exclusion Criteria:

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc Balligand, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Laure Elens</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

